Using an in vitro DCIS model, we recently demonstrated that inflammatory stimuli activated the HER2→NF-κB/COX2/HIF1-α pathway, found to confer a growth advantage to HER2-negative cells. Here, ERBB2 is linked to ductal breast carcinoma in situ.